Our findings also indicate that for individuals at high risk of chronic kidney disease progression, early use of an SGLT2 inhibitor can be particularly advantageous, especially before left ventricular ejection fraction shows signs of significant reduction. Here, SLC5A2 is linked to chronic kidney disease.